Bear said the finding is similar to the situation with many drugs.
"You have to weigh the benefits against the risks. If the benefit is related more to vanity than morbidity, I don't think the risks are tolerable," he said.
Sanofi-Aventis spokeswoman Julissa Viana said rimonabant is not approved for use in children.
"At this point in time it is approved for use in adults who are overweight and obese with cardiovascular risk factors," she said. "We don't encourage its use in children and it has not been studied nor is it indicated for use in children."
The finding is the latest blow for rimonabant, which once was predicted to be a multibillion-dollar seller.
A study last month of the drug in obese heart patients found more than 40 percent of patients who took the drug developed psychiatric problems.
But last month the drugmaker Sanofi said it still believes Acomplia can be a winner and reiterated plans to submit the drug worldwide as a treatment for type 2 diabetes in 2009.
